Schirone, Leonardo
Vecchio, Daniele
Valenti, Valentina
Forte, Maurizio
Relucenti, Michela
Angelini, Annalisa
Zaglia, Tania
Schiavon, Sonia
D’Ambrosio, Luca
Sarto, Gianmarco
Stanzione, Rosita
Mangione, Elisa
Miglietta, Selenia
Di Bona, Anna
Fedrigo, Marny
Ghigo, Alessandra
Versaci, Francesco
Petrozza, Vincenzo
Marchitti, Simona
Rubattu, Speranza
Volpe, Massimo
Sadoshima, Junichi
Frati, Luigi
Frati, Giacomo
Sciarretta, Sebastiano http://orcid.org/0000-0002-8633-6896
Funding for this research was provided by:
Ministero dell’Istruzione, dell’Università e della Ricerca (PRIN 2017N8K7S2)
Sapienza Università di Roma (RG120172B9E42E2C, RG11816433FC0145, AR11715C81FCFF6E)
Istituto Pasteur-Fondazione Cenci Bolognetti (Grant Under 45, 2019 Call)
Ministero della Salute (PNRR-MAD-2022-12376632)
European Union - NextGenerationEU (PNRR-PE0000019-HEAL ITALIA)
Università degli Studi di Roma La Sapienza
Article History
Received: 26 March 2023
Revised: 30 June 2023
Accepted: 16 July 2023
First Online: 11 August 2023
Declarations
:
: AG. is cofounder of Kither Biotech, a pharmaceutical product company developing PI3K inhibitors for the treatment of respiratory diseases, not in conflict with statements made in this article.
: All animal experiments and procedures were approved by the Italian Ministry of Health Ethical Committee and conform to the guidelines from Directive 2010/63/EU of the European Parliament on the protection of animals used for scientific purposes.